Big Pharma Split Corp Class A Total Assets
Big Pharma Split Corp Class A total assets. Based on the latest financial reports, Big Pharma Split Corp Class A (PRM) holds total assets worth CA$33.47 Million CAD (≈ $24.21 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Big Pharma Split Corp Class A market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Big Pharma Split Corp Class A (2017–2025)
Total assets of Big Pharma Split Corp Class A from 2017 to 2025. This chart illustrates how Big Pharma Split Corp Class A's total assets have evolved over time, based on quarterly financial data. See Big Pharma Split Corp Class A share price for real-time trading data and today's change.
Big Pharma Split Corp Class A - Asset Composition Analysis
Big Pharma Split Corp Class A Total Assets Breakdown (December 2025)
Big Pharma Split Corp Class A total assets breakdown as of December 2025. Big Pharma Split Corp Class A's total assets of CA$33.47 Million consist of 98.4% current assets and 1.6% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 4.3% |
| Accounts Receivable | CA$112.09K | 0.4% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Big Pharma Split Corp Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore PRM working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Big Pharma Split Corp Class A's current assets represent 98.4% of total assets in 2025, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 4.3% of total assets in 2025, down from 5.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Big Pharma Split Corp Class A Competitors by Total Assets
Key competitors of Big Pharma Split Corp Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bajaj Holdings & Investment Limited
NSE:BAJAJHLDNG
|
India | Rs851.87 Billion |
|
RiverNorth Flexible Municipal Income Fund II Inc
NYSE:RFMZ
|
USA | $585.45 Million |
|
IGM Financial Inc.
TO:IGM
|
Canada | CA$21.78 Billion |
|
Groep Brussel Lambert NV
BR:GBLB
|
Belgium | €25.06 Billion |
|
Sprott Physical Gold and Silver Trust
TO:CEF
|
Canada | CA$9.34 Billion |
|
Australian Foundation Investment Company Ltd
AU:AFI
|
Australia | AU$9.82 Billion |
|
Golub Capital BDC Inc
NASDAQ:GBDC
|
USA | $8.98 Billion |
|
CI Financial Corp
TO:CIX
|
Canada | CA$11.01 Billion |
Big Pharma Split Corp Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.09 | 0.21 | 2.34 |
| Quick Ratio | 0.09 | 0.21 | 2.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-12.40 Million | CA$-9.96 Million | CA$404.72K |
Big Pharma Split Corp Class A - Advanced Valuation Insights
This section examines the relationship between Big Pharma Split Corp Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.07 |
| Latest Market Cap to Assets Ratio | 0.46 |
| Asset Growth Rate (YoY) | 21.1% |
| Total Assets | CA$31.84 Million |
| Market Capitalization | $14.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values Big Pharma Split Corp Class A's assets below their book value (0.46x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Big Pharma Split Corp Class A's assets grew by 21.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Big Pharma Split Corp Class A (2017–2025)
The table below shows the annual total assets of Big Pharma Split Corp Class A from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$31.84 Million ≈ $23.03 Million |
+21.06% |
| 2024-12-31 | CA$26.30 Million ≈ $19.03 Million |
-0.88% |
| 2023-12-31 | CA$26.53 Million ≈ $19.19 Million |
-32.13% |
| 2022-12-31 | CA$39.10 Million ≈ $28.28 Million |
+3.39% |
| 2021-12-31 | CA$37.81 Million ≈ $27.35 Million |
+64.89% |
| 2020-12-31 | CA$22.93 Million ≈ $16.59 Million |
-15.62% |
| 2019-12-31 | CA$27.18 Million ≈ $19.66 Million |
-19.19% |
| 2018-12-31 | CA$33.63 Million ≈ $24.33 Million |
+3.52% |
| 2017-12-31 | CA$32.49 Million ≈ $23.50 Million |
-- |
About Big Pharma Split Corp Class A
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.